CDC42 and ovarian cancer: Taken together, our identification of R-ketorolac as a Rac1/Cdc42 GTPase inhibitor may help to explain the apparent benefits of racemic ketorolac in human breast and ovarian cancer patient survival, and why other NSAIDs have not yielded comparable findings.